GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cangene Corporation (FRA:YGE) » Definitions » Debt-to-Revenue

Cangene (FRA:YGE) Debt-to-Revenue : 0.00 (As of Oct. 2013)


View and export this data going back to . Start your Free Trial

What is Cangene Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cangene's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2013 was €0.00 Mil. Cangene's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2013 was €0.00 Mil. Cangene's annualized Revenue for the quarter that ended in Oct. 2013 was €72.17 Mil. Cangene's annualized Debt-to-Revenue for the quarter that ended in Oct. 2013 was 0.00.


Cangene Debt-to-Revenue Historical Data

The historical data trend for Cangene's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cangene Debt-to-Revenue Chart

Cangene Annual Data
Trend Jul04 Jul05 Jul06 Jul07 Jul08 Jul09 Jul10 Jul11 Jul12 Jul13
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cangene Quarterly Data
Jan09 Apr09 Jul09 Oct09 Jan10 Apr10 Jul10 Oct10 Jan11 Apr11 Jul11 Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Apr13 Jul13 Oct13
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cangene's Debt-to-Revenue

For the Biotechnology subindustry, Cangene's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cangene's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cangene's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cangene's Debt-to-Revenue falls into.



Cangene Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cangene's Debt-to-Revenue for the fiscal year that ended in Jul. 2013 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 97.269
=0.00

Cangene's annualized Debt-to-Revenue for the quarter that ended in Oct. 2013 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 72.172
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Oct. 2013) Revenue data.


Cangene Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cangene's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cangene (FRA:YGE) Business Description

Traded in Other Exchanges
N/A
Address
Cangene Corporation is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. The company manages its business and evaluate performance based on two operating segments: biopharmaceutical operations and contract services. Revenues are generated from product sales, and contract manufacturing and contract-R&D services.

Cangene (FRA:YGE) Headlines

No Headlines